Financial Performance - In 2019, the company's operating revenue was ¥2,958,622,339.62, a decrease of 59.68% compared to ¥7,338,316,223.18 in 2018[16] - The net profit attributable to shareholders was -¥443,915,811.52, representing a decline of 121.29% from ¥2,084,866,052.69 in the previous year[16] - The net cash flow from operating activities was -¥1,119,993,996.91, a drop of 211.00% compared to ¥1,009,049,053.07 in 2018[16] - The total assets at the end of 2019 were ¥11,653,674,527.93, down 15.98% from ¥13,869,959,247.35 at the end of 2018[16] - The net assets attributable to shareholders decreased by 11.74% to ¥9,974,925,867.75 from ¥11,302,058,975.94 in 2018[16] - The basic earnings per share were -¥0.68, a decline of 121.32% from ¥3.19 in 2018[16] - The weighted average return on equity was -4.13%, a decrease of 23.85% from 19.72% in the previous year[16] - The total revenue for 2019 was approximately ¥2.96 billion, a decrease of 59.68% compared to ¥7.34 billion in 2018[40] - The pharmaceutical industry revenue accounted for 69.95% of total revenue, totaling approximately ¥2.07 billion, down 67.61% from ¥6.39 billion in 2018[41] - The sales volume of the pharmaceutical industry decreased by 32.09% to 5,561 tons in 2019, compared to 8,188 tons in 2018[45] Cash Flow and Investments - The net cash flow from operating activities decreased by 211% to -CNY 1,119,993,996.91, primarily due to a reduction in cash received from sales[59] - Investment activities generated a net cash flow of CNY 1,836,558,933.30, an increase of 2,764.57% compared to CNY 64,112,913.74 in 2018[58] - The company reported a significant increase in investment, with total investments of ¥8,238,800.00, a 311.94% increase compared to ¥2,000,000.00 in the previous year[66] - The company has successfully recovered all principal amounts from its financial investments during the reporting period, indicating effective risk management[115] - The company is actively managing its financial investments to optimize returns while maintaining a focus on liquidity and risk[115] Research and Development - The company has established multiple technology platforms, including a national engineering technology research center for traditional Chinese medicine, enhancing its R&D capabilities[36] - The company has completed the development of 35 enterprise standards and obtained 58 authorized patents, promoting the transformation of the donkey breeding industry[37] - Research and development expenses totaled CNY 205,374,091.23, a decrease of 14.71% from CNY 240,803,070.08 in 2018[54] - The number of R&D personnel increased by 13.09% to 432, with R&D expenses accounting for 6.96% of operating revenue[56] - The research and development focus includes enhancing product efficacy studies and developing trendy, convenient ejiao products for younger consumers[79] Market Strategy and Product Development - The company is actively pursuing digital transformation, new product development, and establishing industry standards to enhance competitiveness[33] - The company has launched a new fresh ready-to-eat Ejiao product, targeting new consumer trends and expanding its market presence[35] - The company is enhancing the competitiveness of the donkey breeding industry to ensure sustainable raw material supply[80] - The company plans to strengthen clinical academic research and develop differentiated products that cater to consumer preferences for convenience and ready-to-eat options[74] - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of the fiscal year[174] Corporate Governance and Shareholder Relations - The company has adhered to its cash dividend policy as outlined in its articles of association, ensuring the protection of minority shareholders' rights[85] - The company has implemented changes in accounting policies in accordance with the new financial instruments standards effective from January 1, 2019[92] - The company maintains a clear separation from its controlling shareholder in terms of business, personnel, assets, institutions, and finance, ensuring operational independence[197] - The company has a well-defined mechanism for selecting its management team, ensuring responsibilities are clearly delineated[196] - The company has not experienced any significant discrepancies in governance practices compared to the regulatory requirements set by the China Securities Regulatory Commission[196] Environmental and Social Responsibility - The company has constructed two wastewater treatment facilities to handle wastewater from its production processes, ensuring compliance with environmental standards[135] - The company has achieved a 100% monitoring rate for wastewater, waste gas, and noise emissions, with all parameters meeting regulatory standards[139] - The company has provided employment for 4,876 individuals through its poverty alleviation initiatives in the donkey breeding industry, resulting in a 20% increase in income for farmers[129] - A total of 120,000 yuan was allocated for poverty alleviation funds, and 300,000 yuan for material support, helping 75,709 registered impoverished individuals to escape poverty[131] - The company has actively engaged in environmental risk assessments and has established emergency response plans for environmental incidents[138] Share Repurchase and Capital Structure - The company plans to repurchase shares with a total amount not less than RMB 750 million and not exceeding RMB 1.5 billion, with a maximum repurchase price of RMB 45 per share[146] - As of December 31, 2019, the total repurchased shares amounted to 6,174,237, which is 0.94% of the total share capital, with a total payment of RMB 227,337,663.91[147] - The company has disclosed multiple announcements regarding the share repurchase progress from May 2019 to February 2020, ensuring compliance with regulations[149] - The total number of ordinary shareholders at the end of the reporting period was 89,404, an increase from 88,455 at the end of the previous month[152] - The company has a total share capital of 654,021,537 shares, with 99.98% being unrestricted shares[145] Leadership and Management Changes - The company appointed Han Yuewei as the new chairman on December 9, 2019, following the resignation of Wang Chuncheng[167] - The company has seen a change in its board with the appointment of new directors and supervisors, including Wu Jun and Weng Jingwen[167] - The management team has a diverse background with experience in various sectors, which is expected to drive the company's growth strategy[170] - The company is focusing on expanding its market presence and enhancing its product offerings through strategic appointments and leadership changes[168] - The company is committed to maintaining its leadership in the industry by leveraging the expertise of its senior management team[170]

国家非物质文化遗产东阿阿胶制作技艺代表性传承人、东阿阿胶总裁：秦玉峰 东阿阿胶股份有限公司 2018 年年度报告全文 东阿阿胶股份有限公司 2018 年年度报告 2019 年 03 月 1 东阿阿胶股份有限公司 2018 年年度报告全文 爱与使命同行，我们勇追那束中医药之光 尊敬的各位股东、长期关心东阿阿胶发展的朋友们： 风云激荡的年代，回溯三千年历史，我们站在时代的风口之下，依旧以千年 滋补精华传承着古老深邃的养生之道，以高瞻远瞩的国际化目标弘扬着传统中医 药文化。过去的 2018 年，是东阿阿胶的重塑之年，既然选择了远方，定要风雨 兼程，我们在既定的方向中不断突破自我，围绕年初确定的目标任务，团结奋斗， 拼搏进取，着力突破"三大瓶颈"、实施"三大工程"，打出了一系列"组合拳"， 在经济下行压力加大、市场竞争日趋激烈的情况下，依然取得了稳定的业绩。我 想，这是东阿人拼搏之下的创新与坚守，也是东阿阿胶发展路上的一曲激荡沉浮。 三千年前的一次回眸，看见阿胶在齐鲁大地耀然而生，从"匠心"到"匠魂"， 东阿阿胶始终追求卓越品质并用创新驱动改革。传承，让时代与时代连接，滋补， 让心与心温暖，阿胶文化承载着民族的记忆， ...

东阿阿胶股份有限公司 2018 年第三季度报告正文 证券代码：000423 证券简称：东阿阿胶 公告编号：2018-42 东阿阿胶股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人秦玉峰、主管会计工作负责人及会计机构负责人(会计主管人员) 吴怀峰声明：保证季度报告中财务报表的真实、准确、完整。 1 东阿阿胶股份有限公司 2018 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 12,226,324,567.87 | 12,376,029,971.71 | | -1.21% | | 归属于上市公司股东的净资产 | 10,467,644,639.23 | 9,8 ...

东阿阿胶股份有限公司 2018 年半年度报告全文 东阿阿胶股份有限公司 2018 年半年度报告 2018 年 08 月 1 东阿阿胶股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人秦玉峰、主管会计工作负责人及会计机构负责人(会计主管人员) 吴怀峰声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及的未来计划、发展战略等前瞻性描述，不构成公司对投资者的 实质承诺，请投资者注意投资风险。 公司主要存在驴皮原料紧缺的风险，具体详见"第四节 经营情况讨论与分 析"，请投资者注意阅读。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 东阿阿胶官方微信号 东阿阿胶官方微信号定位：传递最权威的企业品牌资讯，打造最专业的阿 胶滋补养生平台，构建最有影响力的阿胶粉丝社群。 2 | 目录 | | --- | | 第一节 | 重要提示、目录和释义 | 2 | | --- | --- ...

东阿阿胶股份有限公司 2017 年年度报告 东阿阿胶股份有限公司 2017 年年度报告 2018 年 03 月 1 东阿阿胶股份有限公司 2017 年年度报告 威望素著之下 让世界爱上中医药 国家非物质文化遗产东阿阿胶制作技艺代表性传承人、东阿阿胶总裁：秦玉峰 尊敬的各位股东、长期关心东阿阿胶发展的朋友们： 2017 年，东阿阿胶在各位股东和社会各界的支持和帮助下，在"新算法、 赢未来"的主题映照下，最终带着全年实现销售收入 73.72 亿元、净利润 20.44 亿元的经营成果呈交大家和市场，同时也带领着三千年的历史血脉迈进了改革 开放四十周年的时代路口。回首过去的一年，东阿阿胶承载时代的东风稳步前 进，或许天时地利人和是我们 2017 年发展的基石，但我更想把这一年的收获归 功于这股时代浪潮下，数万阿胶人弘扬民族文化的伟大情怀。 这一年，习近平同志在十九大报告中提出，始终坚定地实施健康中国战略， 要坚持中西医并重，传承发展中医药事业；这一年，《中医药法》正式实施，中 医药产业振兴与发展焕发出了新的生机与活力；这一年，我们看到了消费升级 及老龄化加剧等时代背景下，滋补中药产品不断清晰和开阔的市场前路；这一 年 ...

东阿阿胶股份有限公司 2018 年第一季度报告全文 东阿阿胶股份有限公司 2018 年第一季度报告 2018 年 04 月 1 东阿阿胶股份有限公司 2018 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人秦玉峰、主管会计工作负责人及会计机构负责人(会计主管人员) 吴怀峰声明：保证季度报告中财务报表的真实、准确、完整。 2 东阿阿胶股份有限公司 2018 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 1,695,873,918.74 | 1,676,337,150.97 | 1.17% | | 归属于上市公司股东的净利润（元） | 609,415,777.94 | 604,566,156.92 ...